Home Angiogenesis HER2 inhibitor - Microtubule Associated inhibitor - Antibody-Drug Conjugate Trastuzumab-Emtansine（T-DM1） For research use only.

Trastuzumab-Emtansine（T-DM1）

Synonyms: Ado-Trastuzumab emtansine

Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.This product is supplied as 10mg/ml PBS solution. This product is discontinued. We recommend the replacement products: D4003

Trastuzumab-Emtansine（T-DM1） Chemical Structure

Trastuzumab-Emtansine（T-DM1） Chemical Structure

CAS: 1018448-65-1 (ADC)

Click to purchase products related to Trastuzumab Emtansine（T-DM1）

Purity & Quality Control

Batch: E285101 Purity: 99.59%
99.59

Products often used together with Trastuzumab-Emtansine（T-DM1）

Tucatinib

Trastuzumab Emtansine and Tucatinib show antitumor activity in ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.

Borges VF, et al. JAMA Oncol. 2018 Sep 1;4(9):1214-1220.

Osimertinib (AZD9291)

Trastuzumab Emtansine and Osimertinib may be a promising therapeutic strategy for EGFR-mutant NSCLC.

Monica SL, et al. J Exp Clin Cancer Res. 2017 Dec 4;36(1):174.

Ribociclib

Trastuzumab Emtansine and Ribociclib are under clinical trials for HER2-positive metastatic breast cancer.

Spring LM, et al. NPJ Breast Cancer. 2021 Aug 4;7(1):103.

Lapatinib

Trastuzumab Emtansine has better overall survival and PFS when compared with Lapatinib for treating HER2-Positive, unresectable, locally advanced or metastatic breast cancer.

Squires H, et al. Pharmacoeconomics. 2016 Jul;34(7):673-80.

Capecitabine

Addition of Capecitabine to Trastuzumab Emtansine increases toxic effects.

Cortes J, et al. JAMA Oncol. 2020 Aug 1;6(8):1203-1209.

Trastuzumab-Emtansine（T-DM1） Related Products

Signaling Pathway

HER2 Signaling Pathways

HER2 Signaling Pathway

Choose Selective HER2 Inhibitors

Biological Activity

Description Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.This product is supplied as 10mg/ml PBS solution. This product is discontinued. We recommend the replacement products: D4003
Targets
HER2 [1] Microtubule [1]
In vitro
In vitro

Trastuzumab emtansine significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells.
Cell Research Cell lines EOC cells
Concentrations 2 μg/ml
Incubation Time 24 h
Method

Cells were treated with various concentrations of drug for 24 h.

Chemical Information & Solubility

Molecular Weight 145000 Formulation 10mg/mL in PBS
DAR 3.6 Antibody Trastuzumab
ADC Cytotoxin DM1 Formula N/A
CAS No. 1018448-65-1 (ADC) Storage (From the date of receipt) 1 year -80°C in solvent
Shipping Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

In vitro
Batch:


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What’s the solvent of this ADC drug? And what’s its concentration?

Answer:
The solvent is a PBS solution. The concentration is 10mg/ml.

Tags: buy Trastuzumab-Emtansine（T-DM1） | Trastuzumab-Emtansine（T-DM1） supplier | purchase Trastuzumab-Emtansine（T-DM1） | Trastuzumab-Emtansine（T-DM1） cost | Trastuzumab-Emtansine（T-DM1） manufacturer | order Trastuzumab-Emtansine（T-DM1） | Trastuzumab-Emtansine（T-DM1） distributor